Home > Back to Publisher > Report Information

The Global Market for Antimicrobials and Antifungals: Challenging Resistance to 2016

Spectra Intelligence
December 1, 2006
329 Pages - SKU: SPIN1666363

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Antibiotic resistance is a significant problem which is negatively impacting prescribing patterns, consequently reducing antibiotic usage. The total worldwide market for antibiotics and antifungals was US$25 billion in 2005, but is predicted to fall to between US$15 and US$20 billion by 2016. This forecast is based on a number of factors, but largely due to declining rates of antibiotic prescriptions for respiratory infections - a major segment of the market. Other contributing factors include the loss of market exclusivity for a number of popular branded antibiotics, including Abbott's Biaxin and Pfizer's Zithromax in 2005. Generic competitors of these drugs have already been launched and are set to make serious inroads on the branded market in the years to come.

In this unique market analysis report, The Global Market for Antimicrobials and Antifungals: Challenging Resistance to 2016, the reader will be presented with a comprehensive asessment of the global market for anti-infectives and antifungals. Included in the analysis are therapeutics to combat the lethal microorganisms MRSA, C. difficile, and the highly infectious agents potentially used in bioterrorism. The report also provides current sales and prescription trends for antibiotics and antifungals and a detailed review of the current armamentarium of marketed antibiotics and antifungals. Resistance mechanisms and efforts to target those mechanisms in drug discovery are also discussed. Furthermore, mechanisms of action of current and novel anti-infective therapeutics, side effects, and how differences in dosage formulations can affect their attractiveness to physicians and patients are also detailed. The report also provides an up-to-date extensive list of companies engaged in antibacterial and antifungal drug discovery and lists some of the novel scientific approaches being taken, including chemical biology, toxicogenomics, and computational approaches. It further documents efforts by companies to extend profits on drugs that are off-patent by developing new formulations with additional advantages benefiting patient compliance. Pipeline products and their advantages and disadvantages are also covered in-depth in the market analysis.

Contents List
List of Tables
List of Figures
List of Abbreviations
Executive Summary: Objective of the Report; Research Methodology
CHAPTER 1. INTRODUCTION TO ANTIBIOTICS AND ANTIFUNGALS: 1.1 Pathogenic Bacteria and Fungi; 1.2 Types of Fungi; 1.3 Antibiotic and Antifungal Evaluation; 1.4 Epidemiology of Microbial Disease in the Developed and Developing World; 1.5 The Challenge of Resistance
CHAPTER 2. BACTERIAL AND FUNGAL INFECTIONS AND DISEASES: 2.1 Respiratory Tract Infections; 2.2 Invasive Infections; 2.3 Skin, Eye, Soft Tissue, Joint and Bone Infections; 2.4 Genito-Urinary Tract Infections; 2.6 Sexually Transmitted Infections; 2.7 Gastrointestinal Diseases and Infections; 2.9 Infectious Agents Potentially Utilised in Bioterrorism or Biowarfare; 2.10 Bacterial Infections of the Tropical and Developing World; 2.11 Fungal Diseases and Infections
CHAPTER 3. CLASSIC ANTIBIOTICS AND ANTIFUNGALS: PIPELINE INSIGHTS: 3.0 Classic Antibiotics and Antifungals by Mechanism of Action; 3.1 Cell Wall Synthesis Inhibitors; 3.2 Cell Membrane Disruptors; 3.3 Protein Synthesis Inhibitors; 3.4 Transfer RNA Synthetase Inhibitors; 3.5 Nucleic Acid Synthesis Inhibitors; 3.6 Folic Acid Synthesis Blockers
CHAPTER 4. NEW STRUCTURES AND/OR NOVEL TARGETS: APPROVED OR IN THE PIPELINE: 4.0 New Structures and Novel Targets Recently Approved and in the Pipeline; 4.1 Approved Products; 4.2 Novel Antibiotics; 4.3 Novel Antifungals; 4.4 Novel Antibiotics - New Drug Applications Submitted; 4.5 Novel Antibiotics in Clinical Trials; 4.6 Antibiotics at Preclinical/Early Research Stage
CHAPTER 5. THEWORLDMARKET FOR ANTI-INFECTIVES AND ANTIFUNGALS: 5.1 Global Size of Antibiotic and Antifungal Markets; 5.2 World Market Leaders in Branded Antibiotics; 5.3 US Market Leaders in Branded and Generic Antibiotics and Antifungals; 5.4 Market Shares of Branded and Generic Antibiotics by Class; 5.5 Trends in Antibiotic and Antifungal Sales; 5.6 Factors Affecting Worldwide Antibiotic and Antifungal Sales; 5.7 Market Predictions for Antibiotic and Antifungal Sectors to 2016; 5.8 Potential Impact of Competing Technologies
CHAPTER 6. CHALLENGES IN DEVELOPING ANDMARKETING NEW ANTIBIOTICS: 6.1 Scientific Challenges and Solutions; 6.2 Mechanisms of Antibiotic Resistance; 6.3 Potential Solutions to Antibiotic Resistance; 6.4 Discovery Approaches for New Molecules; 6.5 New Technology for Screening and Toxicological Analysis; 6.6 Converting Limitations into Strengths
CHAPTER 7. COMPANIES MARKETING OR DEVELOPING ANTIMICROBIALS AND ANTIFUNGALS: 7.1 Abbott Laboratories; 7.2 Achaogen; 7.3 Achillion; 7.4 ActivBiotics; 7.5 Advanced Life Sciences; 7.6 Advancis; 7.7 ADVENTRX Pharmaceuticals; 7.8 Alcon Laboratories; 7.9 AlphaRX; 7.10 Arpida; 7.11 Astellas Pharma; 7.12 AstraZeneca Pharmaceuticals; 7.13 Basilea Pharmaceutica; 7.14 Bausch & Lomb; 7.15 Bayer; 7.16 Biovertis; 7.17 Boehringer Ingelheim; 7.18 Bristol-Myers Squibb; 7.19 Centocor; 7.20 Ceragenix Pharmaceuticals; 7.21 Cerexa; 7.22 Chiron; 7.23 Cubist Pharmaceuticals; 7.24 Cumbre Pharmaceuticals; 7.25 Daiichi Sankyo; 7.26 Eli Lilly; 7.27 Enanta Pharmaceuticals; 7.28 GlaxoSmithKline; 7.29 InSite Vision; 7.30 InterMune; 7.31 IntraBiotics Pharmaceuticals; 7.32 Johnson & Johnson; 7.33 King Pharmaceuticals; 7.34 Kyorin; 7.35 Inhibitex; 7.36 Intercell; 7.37 Merck; 7.38 MethylGene; 7.39 Mpex Pharmaceuticals; 7.40 Nabi Biopharmaceuticals; 7.41 Nereus Pharmaceuticals; 7.42 Novartis; 7.43 Novexel; 7.44 NovoBiotic Pharmaceuticals; 7.45 Novozymes; 7.46 Optimer Pharmaceuticals; 7.47 Oragenics; 7.48 Oscient Pharmaceuticals; 7.49 Paratek Pharmaceuticals; 7.50 Pfizer; 7.51 PolyMedix; 7.52 Protez Pharmaceuticals; 7.53 Purdue Pharmaceuticals; 7.54 Quorex Pharmaceuticals; 7.55 Replidyne; 7.56 Rib-X Pharmaceuticals; 7.57 Roche; 7.58 Salix Pharmaceuticals; 7.59 Sanofi-Aventis; 7.60 Schering-Plough; 7.61 Shionogi and Co.; 7.62 TAP Pharmaceutical Products; 7.63 Targanta Therapeutics; 7.64 Theravance; 7.65 Toyama Chemical; 7.66 Vertex Pharmaceuticals; 7.67 ViroPharma; 7.68 Wyeth Pharmaceuticals
LIST OFTABLES: Table 1.1 Common Bacterial Pathogens; Table 1.2 Common Fungal Pathogens; Table 2.1 Bacterial Respiratory Tract Infections and Causative Organisms; Table 2.2 Invasive Infections and Causative Organisms; Table 2.3 Skin, Eye, Soft Tissue, Joint and Bone Infections and Causative Organisms; Table 2.4 Genito-Urinary Tract Infections and Causative Organisms; Table 2.5 Gastrointestinal and Food-Borne Bacterial Infections and Causative Organisms; Table 2.6 Soil and Insect-Borne Bacterial Diseases and Causative Organisms; Table 2.7 The US National Institute of Allergy and Infectious Disease (NIAID) Category A, B and C Priority Bacterial Pathogens for Biodefense Research; Table 2.8 Common Fungal Infections and Causative Organisms; Table 3.1 Recently Approved and Pipeline Cephalosporins; Table 3.2 Beta-Lactam/Beta-Lactamase Inhibitors in the Pipeline; Table 3.3 Recently Approved and Pipeline Carbapenems; Table 3.4 Glycopeptide-Based Anti-Infectives and Descendants in the Pipeline; Table 3.5 Recently Approved and Pipeline Azoles; Table 3.6 Pipeline Aminoglycosides; Table 3.7 Pipeline Macrolides; Table 3.8 Recently Approved and Pipeline Tetracyclines; Table 3.9 Recently Approved and Pipeline Fluoroquinolones; Table 3.10 Recently Approved and Pipeline Rifamycins; Table 4.1 New Antibiotics and Antifungals Approved Since 1999; Table 4.2 New Drug Applications, 2004-2006; Table 4.3 Classic and Novel Antibiotics and Antifungals in Phase-III Clinical Trials; Table 4.4 Classic and Novel Antibiotics and Antifungals in Phase-II Clinical Trials; Table 4.5 Classic and Novel Antibiotics and Antifungals in Phase-I Clinical Trials; Table 4.6 Summary of Antibiotics and Antifungals in Preclinical/Early Research Stage Drug Development; Table 5.1 Worldwide Sales Data for Major Branded Antibiotics, 2005; Table 5.2 Worldwide Sales Data for Major Branded Antifungals, 2005; Table 5.3 US Retail and Hospital Sales Data for Branded and Generic Antibiotics, 2005; Table 5.4 US Retail and Hospital Sales Data for Branded and Generic Antifungals, 2005; Table 5.5 Past, Current, and Future Losses of Patent Protection for Key Antibiotic and Antifungals; Table 5.6 Annual US Disease Cases (Clinic or Hospital Visits), 2006 & 2016; Table 6.1 Mechanisms of Antibiotic and Antifungal Resistance; Table 6.2 Classification of Beta-Lactamases; Table 7.1 Abbott Laboratories’ Anti-Infectives Product Portfolio, 2006; Table 7.2 Achaogen’s Anti-Infective and Antifungal Product Pipeline, 2006; Table 7.3 Achillion’s Anti-Infective Product Pipeline, 2006; Table 7.4 ActivBiotics’ Anti-Infective Product Pipeline, 2006; Table 7.5 Advanced Life Sciences’ Anti-Infective Product Pipeline, 2006; Table 7.6 Advancis’ Current and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.7 ADVENTRX Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.8 Alcon’s Anti-Infective Product Portfolio, 2006; Table 7.9 AlphaRX’s Anti-Infective Product Pipeline, 2006; Table 7.10 Arpida’s Anti-Infective Product Pipeline, 2006; Table 7.11 Astellas Pharma’s Current and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.12 AstraZeneca’s Current and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.13 Basilea Pharmaceutica’s Anti-Infective and Antifungal Product Pipeline, 2006; Table 7.14 Bayer’s Anti-Infective Product Portfolio, 2006; Table 7.15 Biovertis’ Anti-Infective Product Pipeline, 2006; Table 7.16 Bristol-Myers Squibb’s Anti-Infective Product Portfolio, 2006; Table 7.17 Ceragenix Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.18 Chiron’s Anti-Infective Product Portfolio, 2006; Table 7.19 Cubist Pharmaceutical’s Approved and Pipeline Anti-Infective Product Portfolio,; Table 7.20 Cumbre Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.21 Daiichi Sankyo’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.22 Eli Lilly’s Anti-Infective Product Portfolio, 2006; Table 7.23 GlaxoSmithKline’s Approved and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.24 Johnson & Johnson’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.25 King Pharmaceuticals’ Anti-Infective Product Portfolio, 2006; Table 7.26 Kyorin’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.27 Inhibitex’s Anti-Infective Product Pipeline, 2006; Table 7.28 Merck’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.29 MethylGene’s Anti-Infective and Antifungal Product Pipeline, 2006; Table 7.30 Mpex Pharmaceutical’s Anti-Infective Product Pipeline, 2006; Table 7.31 Nabi Biopharmaceutical’s Anti-Infective Product Pipeline, 2006; Table 7.32 Novartis’ Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.33 Novexel’s Anti-Infective and Antifungal Product Pipeline, 2006; Table 7.34 Optimer Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.35 Oscient Pharmaceuticals’ Approved and Pipeline Anti-Infective Product Portfolio,; Table 7.36 Paratek Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.37 Pfizer’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.38 Protez Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.39 Replidyne’s Anti-Infective Product Pipeline, 2006; Table 7.40 Rib-X Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.41 Roche’s Approved and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.42 Sanofi-Aventis’ Approved and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.43 Schering-Plough’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.44 Targanta Therapeutics’ Anti-Infective Product Pipeline, 2006; Table 7.45 Toyama Chemical’s Approved and Pipeline Anti-Infective and Antifungal Product Portfolio,; Table 7.46 Vertex Pharmaceuticals’ Anti-Infective Product Pipeline, 2006; Table 7.47 ViroPharma’s Approved and Pipeline Anti-Infective Product Portfolio, 2006; Table 7.48 Wyeth’s Approved and Pipeline Anti-Infective Product Portfolio, 2006
LIST OF FIGURES: Figure 1.1 Worldwide Causes of Death, 2005; Figure 1.2 Comparison of Causes of Death in High versus Low Income Countries, 2005; Figure 5.1 World Market Shares of Antibiotics, 2005; Figure 5.2 World Market Shares of Antibiotics by Company, 2005; Figure 5.3 US Market Shares of Branded Antibiotics, 2005; Figure 5.4 US Market Shares of Top 10 Generic Antibiotics, 2005; Figure 5.5 US Market Shares of Antifungals, 2005; Figure 5.6 US Market Shares of Branded Antibiotics by Class, 2005; Figure 5.7 US Market Shares of Generic Antibiotics by Class, 2005; Figure 5.8 World Market Shares of Branded Antibiotics by Class, 2005; Figure 5.9 Antibiotics with Increasing Sales Worldwide, 2003-2006; Figure 5.10 Antibiotics with Decreasing Sales Worldwide, 2003-2006; Figure 5.11 Trends in Worldwide Sales of Antifungals, 2003-2006; Figure 5.12 Impact of Four Key Branded Antibiotics Losing Patent Protection in 2005; Figure 5.13 Resistance Rates of Nosocomial Infections, 1998-2003; Figure 5.14 US Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia and Septicaemia Rates by Age Groups, 1999-; Figure 5.15 Rates of Prescriptions Written for Antimicrobial Drugs, 1992-2000; Figure 5.16 Changes in Prescription Rates by Class of Antibiotic, 1992-2000; Figure 5.17 US Rates of Clinic Visits for Infections, 1993-2005; Figure 5.18 Declining Rates of Prescriptions for Respiratory Infections in Children in the US, 1996-; Figure 5.19 US Trends in Infections Requiring Hospitalisation, 1994-2004; Figure 5.20 Changes in Reportable Infection Rates in the US, 1993-2003; Figure 5.21 US Rates of Sexually Transmitted Diseases, 1993-2003; Figure 5.22 US Rates of Clinic Visits (A) or Hospitalisations (B) for per Annum for Common Infections; Figure 5.23 Worldwide Trends in Sales of Macrolides, 2003-2006; Figure 5.24 Worldwide Trends in Sales of Fluoroquinolones, 2003-2006; Figure 5.25 Worldwide Trends in Sales of Penicillins and Cephalosporins, 2003-2006; Figure 5.26 Worldwide Trends in Sales of Carbapenems and Linezolid, 2003-

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

The Global Market for Antimicrobials and Antifungals: Challenging Resistance to 2016

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service